File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study

TitleUsage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study
Authors
KeywordsBiomarker testing turnaround time
EGFR mutation
Epidermal growth factor receptor (EGFR)
Epidermal growth factor receptor tyrosine kinase inhibitor
Non-small cell lung cancer
Real-world data
Issue Date15-Nov-2021
PublisherElsevier
Citation
Lung Cancer, 2023, v. 175, p. 47-56 How to Cite?
Abstract

Objectives

Epidermal growth factor receptor (EGFR) mutations (EGFRm) are common oncogene drivers in non-small cell lung cancer (NSCLC). This real-world study explored treatment patterns and time to receive EGFRm test results in patients with advanced EGFRm NSCLC.

Methods

A cross-sectional medical chart review was completed May–August 2020 in Australia, Canada, Germany, Italy, South Korea, Taiwan, UK, and USA. Eligible patients had advanced NSCLC and a positive EGFRm test result January–December 2017. Data were abstracted from NSCLC diagnosis to end of follow-up (31 March 2020) or patient’s death whichever occurred earlier. The index date was the date of EGFRm confirmation.

Results

223 physicians provided data for 1,793 patients. Patients’ mean age was 64.7 years, 54 % were male, 30.7 % had no history of smoking. Overall, 78 % of EGFRm test results were received ≤ 2 weeks after request (range of median 7–14 days across countries). Median time from advanced NSCLC diagnosis to EGFRm test result was 18 days (median range 10–22 days across countries). Over a third (37 %) of patients received a systemic treatment prior to EGFRm result; chemotherapy (25 %) and EGFR-TKI (15 %) were most commonly prescribed; post-EGFR test-result was EGFR-TKI (68 %); 80 % of patients initiated EGFR-TKI at any time point post-NSCLC diagnosis. Of those receiving a first-line EGFR-TKI post-EGFRm testing, 84 % received a TKI alone, 12 % in combination with chemotherapy, and 3 % with other treatments. Median time from first-line EGFR-TKI initiation post-EGFRm testing to first subsequent treatment was 19.8 months.

Conclusion

Over one-fifth of patients wait >14 days for their EGFRm test results, affecting their likelihood of receiving first-line EGFR-TKI with 20 % of patients never receiving EGFR TKI treatment. There was significant inter-country variability in the proportion of patients receiving EGFR TKIs. Our study highlights the need to improve EGFRm testing turnaround times and treatment initiation across countries.


Persistent Identifierhttp://hdl.handle.net/10722/340990
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.761
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSubramanian, J-
dc.contributor.authorLeighl, NB-
dc.contributor.authorChoi, YL-
dc.contributor.authorChou, TY-
dc.contributor.authorGregg, J-
dc.contributor.authorHui, R-
dc.contributor.authorMarchetti, A-
dc.contributor.authorSilvey, M-
dc.contributor.authorMakin, R-
dc.contributor.authorGillespie-Akar, L-
dc.contributor.authorTaylor, A-
dc.contributor.authorKahangire, DA-
dc.contributor.authorBailey, T-
dc.contributor.authorChau, M-
dc.contributor.authorNavani, N-
dc.date.accessioned2024-03-11T10:48:51Z-
dc.date.available2024-03-11T10:48:51Z-
dc.date.issued2021-11-15-
dc.identifier.citationLung Cancer, 2023, v. 175, p. 47-56-
dc.identifier.issn0169-5002-
dc.identifier.urihttp://hdl.handle.net/10722/340990-
dc.description.abstract<h3>Objectives</h3><p>Epidermal growth factor receptor (<em>EGFR</em>) mutations (<em>EGFR</em>m) are common oncogene drivers in non-small cell lung cancer (NSCLC). This real-world study explored treatment patterns and time to receive <em>EGFR</em>m test results in patients with advanced <em>EGFR</em>m NSCLC.</p><h3>Methods</h3><p>A cross-sectional medical chart review was completed May–August 2020 in Australia, Canada, Germany, Italy, South Korea, Taiwan, UK, and USA. Eligible patients had advanced NSCLC and a positive <em>EGFR</em>m test result January–December 2017. Data were abstracted from NSCLC diagnosis to end of follow-up (31 March 2020) or patient’s death whichever occurred earlier. The index date was the date of <em>EGFR</em>m confirmation.</p><h3>Results</h3><p>223 physicians provided data for 1,793 patients. Patients’ mean age was 64.7 years, 54 % were male, 30.7 % had no history of smoking. Overall, 78 % of <em>EGFR</em>m test results were received ≤ 2 weeks after request (range of median 7–14 days across countries). Median time from advanced NSCLC diagnosis to <em>EGFR</em>m test result was 18 days (median range 10–22 days across countries). Over a third (37 %) of patients received a systemic treatment prior to <em>EGFR</em>m result; chemotherapy (25 %) and EGFR-TKI (15 %) were most commonly prescribed; post-<em>EGFR</em> test-result was EGFR-TKI (68 %); 80 % of patients initiated EGFR-TKI at any time point post-NSCLC diagnosis. Of those receiving a first-line EGFR-TKI post-<em>EGFR</em>m testing, 84 % received a TKI alone, 12 % in combination with chemotherapy, and 3 % with other treatments. Median time from first-line EGFR-TKI initiation post-<em>EGFR</em>m testing to first subsequent treatment was 19.8 months.</p><h3>Conclusion</h3><p>Over one-fifth of patients wait >14 days for their <em>EGFR</em>m test results, affecting their likelihood of receiving first-line EGFR-TKI with 20 % of patients never receiving EGFR TKI treatment. There was significant inter-country variability in the proportion of patients receiving EGFR TKIs. Our study highlights the need to improve <em>EGFR</em>m testing turnaround times and treatment initiation across countries.</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofLung Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBiomarker testing turnaround time-
dc.subjectEGFR mutation-
dc.subjectEpidermal growth factor receptor (EGFR)-
dc.subjectEpidermal growth factor receptor tyrosine kinase inhibitor-
dc.subjectNon-small cell lung cancer-
dc.subjectReal-world data-
dc.titleUsage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study-
dc.typeArticle-
dc.identifier.doi10.1016/j.lungcan.2022.11.009-
dc.identifier.scopuseid_2-s2.0-85142889091-
dc.identifier.volume175-
dc.identifier.spage47-
dc.identifier.epage56-
dc.identifier.isiWOS:001056707900001-
dc.identifier.issnl0169-5002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats